Literature DB >> 15057582

Intradermal methylene blue injection for the treatment of intractable idiopathic pruritus ani: results of 30 cases.

B B Mentes1, M Akin, S Leventoglu, F A Gultekin, M Oguz.   

Abstract

Some cases of idiopathic pruritus anu may be refractory to treatment with dietary and hygienic instructions and short-term topical medications. In this study, we documented our technique and results with methylene blue injection in a large series of patients with intractable idiopathic pruritus ani. The results of 30 adult patients with well-documented intractable idiopathic pruritus ani who were treated with intradermal methylene blue injection are reported. No antibiotic prophylaxis, anesthesia or sedation was used. A total of 15 ml of a 1% methylene blue solution was injected intracutaneously and subcutaneously in the affected perianal area. A second injection (rescue treatment) was offered one month later to patients who declared partial response, and follow-up was restarted. One month after injection, 24 patients (80%) were symptom-free, 5 declared partial remissions, and one patient still had the same degree of pruritus ani. Five patients with partial remission underwent a second methylene blue injection, which provided complete relief in four. Therefore, the early response rate was 80% with single injection and 93.3% (28 of 30) with the rescue treatment. At six months, three recurrences were noted, indicating to a success rate of 83.3% (25 of 30). At 12 months after treatment, 23 patients (76.7%) were symptom free. This study has shown that intradermal methylene blue injection is a safe, simple, fast and efficient method of treating intractable idiopathic pruritus ani.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15057582     DOI: 10.1007/s10151-004-0043-y

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  13 in total

1.  Long-term results of single intradermal 1 % methylene blue injection for intractable idiopathic pruritus ani: a prospective study.

Authors:  N E Samalavicius; T Poskus; R K Gupta; R Lunevicius
Journal:  Tech Coloproctol       Date:  2012-06-06       Impact factor: 3.781

2.  Hidradenitis suppurativa and pruritus ani.

Authors:  Theodor Asgeirsson; Robert Nunoo; Martin A Luchtefeld
Journal:  Clin Colon Rectal Surg       Date:  2011-03

Review 3.  What every gastroenterologist needs to know about common anorectal disorders.

Authors:  Moonkyung Cho Schubert; Subbaramiah Sridhar; Robert R Schade; Steven D Wexner
Journal:  World J Gastroenterol       Date:  2009-07-14       Impact factor: 5.742

4.  Pruritus ani.

Authors:  Seok-Gyu Song; Soung-Ho Kim
Journal:  J Korean Soc Coloproctol       Date:  2011-04-30

Review 5.  Cellular and molecular actions of Methylene Blue in the nervous system.

Authors:  Murat Oz; Dietrich E Lorke; Mohammed Hasan; George A Petroianu
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

Review 6.  Pruritus ani.

Authors:  S Siddiqi; V Vijay; M Ward; R Mahendran; S Warren
Journal:  Ann R Coll Surg Engl       Date:  2008-09       Impact factor: 1.891

7.  Intradiscal methylene blue injection for the treatment of chronic discogenic low back pain.

Authors:  Baogan Peng; Yingmin Zhang; Shuxun Hou; Wenwen Wu; Xiaobing Fu
Journal:  Eur Spine J       Date:  2006-02-22       Impact factor: 3.134

8.  Effect of Intradiscal Methylene Blue Injection for the Chronic Discogenic Low Back Pain: One Year Prospective Follow-up Study.

Authors:  Soo-Hyun Kim; Sang-Ho Ahn; Yun-Woo Cho; Dong-Gyu Lee
Journal:  Ann Rehabil Med       Date:  2012-10-31

9.  Effectiveness of Methylene Blue in the Prevention of Stifle Joint Arthrofibrosis in Rabbit Models.

Authors:  Hamid Namazi; Mohammad J Emami; Fatemeh Dehghani Nazhvani; Ali Dehghani Nazhvani; Zeinab Kargarshouroki
Journal:  Arch Bone Jt Surg       Date:  2019-05

10.  Effect of honey on peridural fibrosis formation after laminectomy in rats: a novel experimental study.

Authors:  Majid Reza Farrokhi; Mohammad Vasei; Saeed Fareghbal; Atefeh Bakhtazad
Journal:  Evid Based Complement Alternat Med       Date:  2011-01-23       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.